Three-year outcome of local injection of autologous stromal vascular fraction cells and microfat in refractory perianal fistulas of Crohn’s disease

Stem Cell Research & Therapy

Françoise Dignat-George¹  Fanny Grimaud²  Julie Veran²  Florence Sabatier²  Jérémy Magalon²  Marc Leone³  Caroline Prost⁴  Carine Visee⁵  Laura Beyer-Berjot⁵  Fanny Houser⁶  Lucas Guillo⁶  Ariadne Desjeux⁶  Jean-Charles Grimaud⁶  Mélanie Serrero⁶  Maxime Abellan⁷  Cécile Philandrianos⁷  Elisabeth Jouve⁸ 

[1] C2VN, INSERM UMR 1263, Faculté de Pharmacie de Marseille, Aix Marseille University;Cell Therapy Department, INSERM CBT-1409, Assistance Publique Hôpitaux de Marseille, Aix-Marseille University;Department of Anaesthesia and Intensive Care, Assistance Publique Hôpitaux de Marseille;Department of Radiology, Assistance Publique Hôpitaux de Marseille;Digestive Surgery Department, Assistance Publique Hôpitaux de Marseille;Gastroenterology Department, Assistance Publique Hôpitaux de Marseille, University Hospital of Marseille Nord (AP-HM);Plastic Surgery Department, Assistance Publique Hôpitaux de Marseille;Statistical Department, Assistance Publique Hôpitaux de Marseille;

关键词: Stromal vascular fraction;    Crohn’s disease;    Perianal fistulas;    Long-term outcome;   

DOI  :  10.1186/s13287-022-02738-x

来源: DOAJ

【 摘 要 】

Abstract Perianal fistulas in Crohn's disease are frequent and disabling, with a major impact on patients' quality of life. Cell-based therapy using mesenchymal stem cells represents new hope for these patients, but long-term efficacy remains challenging. In a pilot study, including patients with refractory complex perianal fistulas, autologous adipose-derived stromal vascular fraction (ADSVF) combined with microfat achieved combined remission in 60% of cases, with a good safety profile at 1 year. The purpose of this study is to assess whether these results were maintained at longer term. The safety and efficacy data of the ten patients were evaluated retrospectively 3 years after injection on the basis of clinical and radiological data. MRI were analysed according to the MAGNIFI-CD score. No adverse event was attributed to the experimental stem-cell treatment. Combined remission was achieved in 7 patients (70%) and associated with a significant improvement in the MAGNIFI-CD MRI score. In conclusion, the safety and efficacy of ADSVF and microfat injection in Crohn's disease fistulas were maintained at 3 years, demonstrating that this innovative strategy is effective in producing a long-lasting healing effect. The ongoing multicentre randomized placebo-controlled trial (NCT04010526) will be helpful to define the place for this approach in the current therapeutic arsenal.

【 授权许可】

Unknown